Guardant Shield™ Multi-Cancer Detection

Guardant Shield™ is an FDA-approved blood-based test for colorectal cancer screening. It offers a non-invasive alternative to colonoscopy for average-risk adults aged 45 and older, using ctDNA analysis from a simple blood draw.

Shield MCD has received FDA breakthrough device designation in June 2025. This includes eight cancer types – bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreatic cancer.

Shield MCD covers 10 cancer types:

• Bladder
• Breast
• Colorectal
• Esophageal
• Gastric
• Liver
• Lung
• Ovarian
• Pancreatic
• Prostate

Intended For:

• Average-risk adults aged 45 and older
• No pregnancy
• No known cancer history

Standard blood draw — specific tube per Guardant Shield kit

40 mL peripheral blood collected into 4 × Streck Cell-Free DNA BCT® tubes. Collected by a licensed healthcare professional.

Guardant Shield™ is available through Codex Genetics as the authorised Guardant Health distributor in Hong Kong.

Sensitivity in the 6 most aggressive cancers (defined as the shortest surviail rates) Included esophageal, gastric, hepatocellular, lung, ovarian, and pancreatic cancers.

Disclaimer: A positive result means an abnormal signal was detected. Although a positive result raises concern for the presence of cancer, it is not a diagnosis of cancer. In fact, most people with a positive result do not have cancer. Contact the healthcare provider who ordered the test regarding any clinically indicated follow-up.